Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo pós-comercialização da massa MagnetOs comparada com o autoenxerto em pacientes submetidos à artrodese póstero-lateral lombar (PROOF)

3 de novembro de 2026 atualizado por: Kuros Biosurgery AG

Um estudo prospectivo, randomizado e de centro único para avaliar a segurança e o desempenho da massa MagnetOs em comparação com o autoenxerto em pacientes submetidos à fusão posterolateral lombar/toracolombar (PLF) instrumentada em dois níveis

This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.

In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.

In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.

Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Irvine, California, Estados Unidos, 92697
        • The Regents of the University of California- Irvine Campus
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Corewell Health
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63130
        • The Washington University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Rothman Orthopaedic Institute
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37209
        • Tennessee Orthopaedic Alliance
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • University of Washington

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
  • Male or female patient ≥ 18 years old.
  • Patients with segmental mechanical spinal instability requiring arthrodesis surgery.

Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:

  1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),

  2. decreased disc height by > 2 mm, but dependent upon the spinal level

  3. Grade II or more listhesis

  4. TLICS equal or greater than 5

  5. Unstable burst fracture

    • Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.

Exclusion Criteria:

  • Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
  • Had prior PLF fusion or attempted PLF fusion at the involved levels.
  • Had previous decompression at the involved levels.
  • Women who are or intend to become pregnant within the next 12 months.
  • To treat conditions in which general bone grafting is not advisable.
  • In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
  • In case of significant vascular impairment proximal to the graft site.
  • In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
  • In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  • When intraoperative soft tissue coverage is not planned or possible.
  • Receiving treatment with medication interfering with calcium metabolism.
  • Has degenerative disc disease (DDD) related to a benign or malignant tumor.
  • Has history or presence of active malignancy.
  • Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  • Is involved in active litigation relating to his/her spinal condition.
  • Has participated in an investigational study within 30 days prior to surgery for study devices.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: MagnetOs Easypack Putty

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device; MagnetOs Easypack Putty

MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side.

Comparador Ativo: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone

Interventions

  • Procedure: Instrumented posterolateral spine fusion
  • Device: Demineralized Bone Matrix or Fibers mixed with local autograft bone

Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Radiographic Fusion by CT Scan
Prazo: Month 12

The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

Month 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Radiographic Fusion by Plain Radiographs
Prazo: Month 6, Month 12

The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs.

Month 6, Month 12
Radiographic Fusion by CT Scan
Prazo: Month 6

The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes.

Month 6
Functional Outcome by Oswestry Disability Index Questionnaire
Prazo: Screening, Week 2, Month 3, 6, and 12

Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden.

Screening, Week 2, Month 3, 6, and 12
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
Prazo: Screening, Week 2, Month 3, 6, and 12

Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable.

Screening, Week 2, Month 3, 6, and 12
Neurologic Status by Physical Exam
Prazo: Screening, Week 2, Month 3, 6, and 12

Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise.

Screening, Week 2, Month 3, 6, and 12
Success Rate
Prazo: Week 2, Month 3, 6, and 12

Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery.

Week 2, Month 3, 6, and 12

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Safety Endpoint - number of patients with Adverse Events
Prazo: 12 Months

The number of patients with Adverse Events from Screening up to Month 12 after surgery.

12 Months
Safety Endpoint - number of patients with Serious Adverse Events
Prazo: 12 Months

The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery

12 Months
Safety Endpoint - number of patients with Adverse Device Effects
Prazo: 12 Months

The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery.

12 Months
Safety Endpoint - number of patients with Device Related Complications
Prazo: 12 Months

The number of patients with any complications considered to device related with 12 months after surgery.

12 Months
Health Economic - Duration of Surgery
Prazo: 12 Months

Duration of surgery in minutes.

12 Months
Health Economic - Duration of Hospitalization
Prazo: 12 Months

Duration of hospital stay in days.

12 Months
Health Economic - Return to Work
Prazo: 12 Months

Time to return to work in days.

12 Months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Cesar Silva, MD, Kuros BioSciences B.V.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de dezembro de 2024

Conclusão Primária (Estimado)

2 de dezembro de 2027

Conclusão do estudo (Estimado)

30 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

18 de dezembro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de dezembro de 2020

Primeira postagem (Real)

22 de dezembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

4 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • MAG-920-023

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .